S&P 500   3,241.59 (-2.35%)
DOW   26,846.88 (-2.93%)
QQQ   263.69 (-1.19%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,241.59 (-2.35%)
DOW   26,846.88 (-2.93%)
QQQ   263.69 (-1.19%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,241.59 (-2.35%)
DOW   26,846.88 (-2.93%)
QQQ   263.69 (-1.19%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
S&P 500   3,241.59 (-2.35%)
DOW   26,846.88 (-2.93%)
QQQ   263.69 (-1.19%)
AAPL   106.92 (+0.07%)
MSFT   199.57 (-0.41%)
FB   246.80 (-2.27%)
GOOGL   1,423.32 (-1.91%)
AMZN   2,891.57 (-2.14%)
NVDA   490.49 (+0.60%)
TSLA   440.96 (-0.27%)
BABA   270.89 (-0.56%)
CGC   15.57 (-4.83%)
GE   6.25 (-9.16%)
MU   48.87 (-3.69%)
AMD   76.46 (+2.04%)
T   28.31 (-2.14%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.61 (-2.21%)
NFLX   478.96 (+1.92%)
DIS   124.37 (-3.31%)
BAC   24.11 (-4.36%)
BA   156.61 (-2.81%)
Log in
NASDAQ:CMRX

Chimerix Stock Forecast, Price & News

$2.66
-0.19 (-6.67 %)
(As of 09/21/2020 02:18 PM ET)
Add
Compare
Today's Range
$2.60
Now: $2.66
$2.75
50-Day Range
$2.30
MA: $2.82
$3.41
52-Week Range
$1.19
Now: $2.66
$3.88
Volume22,917 shs
Average Volume666,262 shs
Market Capitalization$165.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Read More
Chimerix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CMRX
CUSIPN/A
Phone919-806-1074

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Book Value$1.79 per share

Profitability

Net Income$-112,580,000.00
Net Margins-859.64%

Miscellaneous

Employees82
Market Cap$165.45 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$2.66
-0.19 (-6.67 %)
(As of 09/21/2020 02:18 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Chimerix (NASDAQ:CMRX) Frequently Asked Questions

How has Chimerix's stock been impacted by COVID-19?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CMRX stock has increased by 84.7% and is now trading at $2.66.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Chimerix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chimerix
.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Chimerix
.

How were Chimerix's earnings last quarter?

Chimerix Inc (NASDAQ:CMRX) issued its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. The biopharmaceutical company earned $1.40 million during the quarter, compared to the consensus estimate of $1.17 million. Chimerix had a negative net margin of 859.64% and a negative return on equity of 31.42%.
View Chimerix's earnings history
.

What price target have analysts set for CMRX?

1 equities research analysts have issued 1-year price objectives for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chimerix's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price.
View analysts' price targets for Chimerix
.

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)
  • Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)
  • Mr. Michael A. Sherman, CEO & Pres (Age 53)
  • Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology Officer
  • Dr. Randall Lanier Ph.D., Chief Science Officer

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by many different institutional and retail investors. Top institutional investors include Opaleye Management Inc. (3.38%), FMR LLC (1.31%), FMR LLC (1.31%), Two Sigma Advisers LP (1.29%), Point72 Asset Management L.P. (1.01%) and Jacobs Levy Equity Management Inc. (0.78%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix
.

Which institutional investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, UBS Group AG, Point72 Asset Management L.P., Nuveen Asset Management LLC, Goldman Sachs Group Inc., RBF Capital LLC, and Man Group plc. Company insiders that have sold Chimerix company stock in the last year include Garrett Nichols, and Martha J Demski.
View insider buying and selling activity for Chimerix
.

Which institutional investors are buying Chimerix stock?

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Jacobs Levy Equity Management Inc., Worth Venture Partners LLC, Two Sigma Advisers LP, Public Employees Retirement System of Ohio, Russell Investments Group Ltd., Jane Street Group LLC, and Vanguard Capital Wealth Advisors. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $2.66.

How big of a company is Chimerix?

Chimerix has a market capitalization of $165.45 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.